UK markets open in 6 hours 14 minutes

ALK-Abelló A/S (ALK-B.CO)

Copenhagen - Copenhagen Real-time price. Currency in DKK
Add to watchlist
2,696.00-36.00 (-1.32%)
At close: 04:59PM CET
Full screen
Previous close2,732.00
Open2,688.00
Bid0.00 x 0
Ask2,696.00 x 0
Day's range2,626.00 - 2,700.00
52-week range2,252.00 - 3,500.00
Volume24,107
Avg. volume10,642
Market cap29.463B
Beta (5Y monthly)0.19
PE ratio (TTM)266.64
EPS (TTM)10.11
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date16 Mar 2017
1y target est3,512.33
  • Globe Newswire

    ALK – Financial calendar for the 2022 financial year

    2022 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Silent period11 January 2022Annual report 20218 February 2022Annual General Meeting to be held at ALKBøge Allé 12970 Hørsholm, Denmark Written requests to have specific business transacted at the AGM will be included in theagenda if received by the company on1 February 2022 at the latest(may be e-mailed to investor@alk.net)16 March 20224.00 p.m.Silent period14 April 2022Three-month interim report (Q1) 202212 May 2022Silent p

  • Globe Newswire

    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

    ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) reports the following transactions: 1.Details of the person discharging managerial responsibility / person closely associateda)NameSøren Niegel2.Reason for the notificationa)Position/statusMember of the Board of Managementb)Initial notification/amendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitora)NameALK-Abelló A/Sb)LEI529900SGCREUZCZ7P0204.Details of the transactio

  • Globe Newswire

    Nine-month interim report (Q3) 2021

    ALK delivers Q3 sales growth of 20%, with tablet sales up 41% (unaudited) ALK’s revenue grew strongly during Q3 following broad-based growth in all of its regions. Total revenue increased 20% for the quarter, as tablet sales growth surged to 41% and legacy products continued their sales recovery as allergy markets normalised further. These positive results contributed to an EBITDA increase of 114% in reported currency. The outlook has been updated to reflect the year-to-date performance. Q3 2021